TERBINAFINE PHARMACOKINETICS FOLLOWING SINGLE-DOSE ORAL ADMINISTRATION IN RED-EARED SLIDER TURTLES ( TRACHEMYS SCRIPTA ELEGANS): A PILOT STUDY

J Zoo Wildl Med. 2021 Jun;52(2):520-528. doi: 10.1638/2020-0079.

Abstract

In this pilot study, the pharmacokinetics of terbinafine were determined in six apparently healthy red-eared slider turtles (Trachemys scripta elegans) after a single PO administration. Terbinafine suspension (15 mg/kg, once) was administered via gavage tube to all turtles. Blood samples were collected immediately before (time 0) and at 1, 2, 4, 8, 24, and 48 h after drug administration. Plasma terbinafine concentrations were quantified by ultra-performance liquid chromatography-mass spectrometry, and noncompartmental pharmacokinetic analysis was performed. None of the animals showed any adverse responses following terbinafine administration. Mean area under the curve from time 0 to 24 h was 1,213 h × ng/ml (range 319-7,309), mean peak plasma concentration was 201.5 ng/ml (range 45.8-585.3), mean time to maximum plasma concentration was 1.26 h (range 1-4), mean residence time was 7.71 h (range 3.85-14.8), and mean terminal half-life was 5.35 h (range 2.67-9.83). The administration of terbinafine (15 mg/kg, PO) may be appropriate for treatment of select fungal organisms with low minimum inhibitory concentrations in red-eared slider turtles but may require q12h administration even for organisms with low minimum inhibitory concentrations. Multiple-dose studies as well as clinical studies are needed to determine ideal dosages and efficacy.

Publication types

  • Clinical Trial, Veterinary

MeSH terms

  • Animals
  • Antifungal Agents / blood
  • Antifungal Agents / pharmacokinetics*
  • Area Under Curve
  • Female
  • Half-Life
  • Pilot Projects
  • Terbinafine / blood
  • Terbinafine / pharmacokinetics*
  • Turtles / blood*

Substances

  • Antifungal Agents
  • Terbinafine